Advances in blockchain will be of immense help to the pharma industry and a lecture in that regards will be delivered by Dr. Alex Zhavoronkov, founder and CEO of Insilico Medicine at the Singularity University Exponential Medicine Program in San Diego on Wednesday November 8 in Session XVIII – Future of Pharma.
According to a press note Dr. Zhavoronkov’s session will focus on recent advances in the convergence of the next-generation artificial intelligence and blockchain technologies for drug discovery, biomarker development and personal data management.
Exponential Medicine is a reimagination of the medical conference, providing world-class faculty, innovators and organizations from across the biomedical and technology spectrum. The unique and intensive four-day event explores and leverages the convergence of fast moving technologies in the reinvention and future of health and medicine. Exponential Medicine is the world’s most venerated program in the biomedical technologies, and presenting at the event provides a unique opportunity to share with some of the most respected people in the field.
Dr. Zhavoronkov believes that massive convergence of the recent advances in a number of fields including deep learning, blockchain, high performance computing and other IT technologies will prominently dictate the next paradigm shift in human development.
Insilico Medicine, Inc. is an artificial intelligence company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D resources in Belgium, Russia, and the UK sourced through hackathons and competitions.
The company utilizes advances in genomics, big-data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company is pursuing internal drug discovery programs in cancer, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging.
Through its Pharma.AI division, Insilico provides advanced machine learning services to biotechnology, pharmaceutical, and skin care companies, foundations and national governments globally. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact.